The next event in ACI’s Women Leaders in Law series, on July 25 & 26 in Boston, brings together in-house and private practice professionals from the pharmaceutical, biotechnology, and medical device industries.
An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.
3D-printed organs and tissues are now a reality, but questions remain over their patentability, says Gabriel Di Blasi of Di Blasi, Parente & Associados.
While registering trademarks for cannabis products at the USPTO is currently impossible, brands are applying creative solutions to the problem, says Leon Steinberg of Dennemeyer.
The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.
Brazil’s patent law does not allow methods of treatment to be patented, but there are other means of getting protection, according to Kene Gallois and Samantha Salim of Daniel Law.
It is challenging but not impossible to protect software innovations in Mexico, according to Alejandro Moreno Hernández of Uhthoff, Gomez Vega & Uhthoff.
ACI’s 17th Global Summit on Life Sciences Patents returns to New York on May 15-17, 2019, to provide practical insights on how to maximise your patent term and develop strategies to enhance protections for your patent portfolio.
The political influence on patent rights during Brazil’s general election in October has set a worrying precedent, writes Gabriel Di Blasi of Di Blasi Parente & Associados.
Hector Chagoya and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril examine how Mexico applies the Budapest Treaty, which covers microorganisms in the patent process.